Last reviewed · How we verify
PREDNISOLONE ACETATE
At a glance
| Generic name | PREDNISOLONE ACETATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1955 |
Approved indications
Common side effects
- Elevation of intraocular pressure (IOP)
- Posterior subcapsular cataract formation
- Delayed wound healing
- Secondary ocular infection (bacterial, fungal, viral)
- Transient burning and stinging upon instillation
- Ocular irritation
- Allergic reactions
- Eye pain
- Foreign body sensation
- Headache
- Pruritus
- Rash
Serious adverse events
- Development of glaucoma
- Optic nerve damage
- Fungal infection of cornea
- Viral infection of cornea
- Corneal ulceration
- Keratitis
- Acute anterior uveitis
- Perforation of the globe
- Conjunctival hyperemia
- Ptosis
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PREDNISOLONE ACETATE CI brief — competitive landscape report
- PREDNISOLONE ACETATE updates RSS · CI watch RSS